QualityStocks
  The QualityStocks Daily Newsletter for Friday December 18th, 2009 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters

1.

OTC Picks (MMUH)

2.

Penny Omega Stocks (APRU)

3.

Small Cap Sentinel (GNAU)


The QualityStocks Daily

Clean Energy Fuels Corp. (CLNE)

All About Trends reported this week on Clean Energy Fuels Corp. (CLNE), DrStockPick.com did earlier, and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 2001, Clean Energy Fuels Corp. is the leading provider of compressed natural gas (CNG) and liquefied natural gas (LNG) for transportation in North America. The Company has their corporate headquarters in Seal Beach, California.  Trading on the NASDAQ, the Company has a broad customer base in the refuse, transit, shuttle, taxi, intrastate and interstate trucking, airport, and municipal fleet markets.

Clean Energy designs, builds, operates, and maintains natural gas fueling stations offering convenience, state-of-the-art technology, and safety. Across the U.S. and Canada, they fuel more than 17,500 vehicles per day at more than 195 locations. Through their industry experience and expertise, they also assist their customers in understanding current state and federal clean-air regulations, and internal mandates.

Clean Energy Fuels' customers include Los Angeles International Airport, Phoenix Sky Harbor International Airport, SuperShuttle, Foothill Transit, Waste Management, Dallas-Ft. Worth International Airport, SYSCO Foods, Ft. Worth Transportation Agency, Denver International Airport, Denver RTD, MTDB of San Diego, and the U.S. Navy. Clean Energy owns and operates LNG production plants in Willis, Texas and in Boron, California. These have a combined capacity of 260,000 LNG gallons per day and their design is to expand to 340,000 LNG gallons per day as demand increases.

They also own and operate a landfill gas facility in Dallas, Texas. This facility produces renewable methane gas or biogas for delivery in the nation's gas pipeline network. Clean Energy also owns and operates BAF of Dallas, Texas. They are a leading provider of natural gas vehicle systems and conversions for taxis, limousines, vans, pick-up trucks, and shuttle buses.

Last week, Veolia Transportation Services, Inc. awarded Clean Energy Fuels Corp. a contract to build, operate, and maintain a compressed natural gas (CNG) bus fueling station at Veolia facilities in downtown Los Angeles. Veolia Transportation Services, Inc. is North America's largest private provider of public transit services. Construction of the new Veolia/Clean Energy CNG station will begin in January 2010, with completion set for mid 2010. CNG fuel requirements are projected at more than 420,000 gasoline-gallon-equivalents in the first year of the Veolia station's operations.

Clean Energy Fuels Corp. (CLNE) closed today at $14.03 up 0.57 percent. Volume was 757,125.

Advaxis, Inc. (ADXS)

This week, SmallCap Voice reported on Advaxis, Inc. (ADXS), Monster Stox, Stock Picks, Titan Stocks, Stock Rich, HotOTC.com, OTC Picks, Cool Penny Stocks, Standout Stocks did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Advaxis, Inc. is developing proprietary Listeria monocytogenes (Lm) cancer vaccines. The Company bases these on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis Incorporated trades on the OTCBB and the Company has their corporate headquarters in North Brunswick, New Jersey.

Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer. The unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously, coordinating innate, humoral (antibody), and cellular adaptive immune responses in an effective response to existing cancers and other diseases. In pre-clinical research, the Company's Listeria technology has been able to demonstrate consistently complete therapeutic responses resulting in complete tumor regression.

Listeria has a unique life cycle. It infects Antigen Presenting Cells (APC), which are cells that activate immune cells and tell them what to attack. Listeria becomes positioned to have the maximum effect on the immune system in terms of directing it against specific targets. Listeria has the ability to stimulate both helper T cells (CD4+) and killer T cells (CD8+). Both are necessary for an antitumor response and it is unusual for a single pathogen to stimulate both in the way Listeria does.

In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against the tumor-associated antigen HPV-16-E7 underwent administering safely to fifteen women with advanced metastatic cancer of the cervix. The design and powering of this first trial of an Lm vaccine in humans was not to prove efficacy. However, Advaxis believes an efficacy signal was observed that will be further explored in two planned Phase II trials in the United States and India in cervical cancer and its predecessor condition, cervical intraepithelial neoplasia (CIN). Advaxis has nine distinct cancer fighting constructs in various stages of development, both directly and with academic collaborators.

In September, the Company announced that The United States Patent and Trademark Office (USPTO) granted and issued Advaxis, Inc. patent 7,588,930 "Compositions and Methods for Enhancing Immunogenicity of Antigens." This patent expands the Company's intellectual property portfolio to cover another family of adjuvant proteins based upon the Lm protein Act-A.

On Tuesday, Advaxis, Inc. reported that they would collaborate with the Gynecologic Oncology Group (GOG). They are a collaborative research group of the National Cancer Institute (NCI). Advaxis will collaborate with them in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

Advaxis, Inc. (ADXS) closed today at $0.1399 up 11.03 percent. Volume was 794,848.

China Crescent Enterprises, Inc. (CCTR)

SmallCap Voice, PennyOmega.com, Stock Marketing Inc., DrStockPick.com, Stock Stars, HotOTC.com, Stock Rich, Cool Penny Stocks, Penny Invest, StockEgg.com, OTC Picks, and Penny Stock Finder all reported on China Crescent Enterprises, Inc. (CCTR), and we highlight the Company, here at the QualityStocks Daily Newsletter.

China Crescent Enterprises, Inc. is a technology leader in the rapidly developing Chinese market. The Company specializes in software engineering, high quality software development, and digital multimedia outsourcing services delivered to customers worldwide. China Crescent Enterprises is also a systems integrator and value added reseller of major global hardware brands in the Chinese domestic market. China Crescent Enterprises, Inc. has their headquarters in Dallas, Texas, with operations in Shanghai and Beijing, China. They trade on NASDAQ's OTC Bulletin Board.

Crescent assists Western clients in realizing the advantages of the high quality, low cost technology products and services available from China. They also assist Western clients in localizing products and services to realize the significant growth potential available by expanding into the Chinese Market. China Crescent, through understanding the differences in business processes, communications, and cultures between the Untied States and China, provides their customers with an environment for global relationships and transactions.

China Crescent Enterprises, Inc. and NuMobile, Inc. entered into a partnership agreement this year to combine NuMobile's smartphone and mobile computing technology solutions with China Crescent's systems integration expansion into East Africa in the launch of WiMax services in Africa.

China Crescent Enterprises, Inc. reported over $40 million in revenue in both 2007 and 2008. The Company has forecasted reporting $50 million in profitable revenue in 2009. China Crescent is now registering in China to provide E-Commerce services to improve their sales potential of smartphone and mobile computing solutions.

Today, China Crescent Enterprises, Inc. released an on-demand Webcast focused on a pending $36 million, three-year contract with Aoyuan Electronic Co. Ltd. located in Dalian, China, that management expects to close by year-end. China Crescent would provide outsourcing services for the client. This is to include desktop computing and telecommunications. China Crescent launched their outsourcing services business line earlier this year. They expect the impact of their initial success to show in fourth quarter 2009 financials.

China Crescent Enterprises, Inc. (CCTR) closed Friday's trading session at $0.0220 for no change. Volume was 3,962,324.

Freestone Resources, Inc. (FSNR)

We are highlighting Freestone Resources, Inc. (FSNR), here at the QualityStocks Daily Newsletter.

Freestone Resources, Inc. is an oil and gas technology-development company. Their continuing corporate goal is to develop new technologies that allow them to utilize these resources in an environmentally responsible and cost effective way. With their headquarters in Dallas, Texas, the Company trades on the OTCBB.

Freestone Resources Inc.'s mission is to deliver a competitive rate of return to their shareholders, partners, and investors through the development of their hydrocarbon recovery technologies. Through the development of these technologies, their dedication is to environmental improvements in the conventional and unconventional hydrocarbon extraction industry.

Freestone owns exclusive license agreements to utilize EncapSol. This chemical solvent could separate, extract, and recycle hydrocarbon contaminants from ground soils, tar sands, vessels, and other materials. Freestone Resources, Inc. announced in October that the Company's primary focus is on the new proprietary, non-toxic and environmentally friendly EncapSol Oil Extraction and environmental cleanup technology in their exclusive world territories after the recent acquisition of Earth Oil Services, Inc.

EncapSol uniquely and cleanly breaks the molecular bonds that bind hydrocarbon (oil) molecules to sand, clay, rock, water, and other materials. It dislodges the oil for easier extraction, while leaving the sand, clay, gravel, and water by-products free of hydrocarbon contaminants.

Freestone intends to form clean oil joint ventures with investors and industrial market-leaders to build, own, and operate mobile and fixed-site EncapSol Oil Recovery machines. These EOR machines will generate clean oil sales revenues, and create clean oil jobs in three distinct oil-recovery markets. These are oil sludge environmental cleanup, enhanced downhole oil recovery, and tar sands and oil shale extraction.

Yesterday, Freestone Resources, Inc. announced that they began to conduct laboratory demonstrations of the EncapSol solvent technology to prominent Oil and Gas Companies. They have entered into a joint venture on a lease in Corsicana, Texas with Haas Petroleum, LLC. The management and scientists at Freestone have begun presenting information on EncapSol, and performing demonstrations of the solvent technology.

The ultimate goal of these meetings is to form strategic relationships and partnerships with companies that can benefit from their EncapSol technology. This is as a downhole recovery agent, a fracing additive, an environmental cleanup technology, and as a state of the art oil sand and oil shale extraction solvent.

Freestone Resources, Inc. (FSNR) closed Friday's session at $0.17 up 6.25 percent. Volume was 124,989.

James River Coal Co. (JRCC)

Last week ChartAdvisor.com reported on James River Coal Co. (JRCC), Today's Financial News, The Stock Advisors, The Bull Report did earlier, and we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 1988, James River Coal Co. through their subsidiaries engages in mining, processing, and selling bituminous, steam, and industrial-grade coal in eastern Kentucky and southern Indiana. The Company has six operating subsidiaries and they are the sixth largest coal producer in Central Appalachia and the third largest in the Illinois Basin. James River Coal Co. trades on NASDAQ and they have their headquarters in Richmond, Virginia. They also have offices in Lexington and London, Kentucky.

The Company's operations are in the Central Appalachian and Illinois coal basin. James River Coal Co. has, as of December 31, 2008, six mining complexes including 17 underground mines, 14 surface mines, and 10 preparation plants. Five of the plants have integrated rail load out facilities and three use a common load out facility at a separate location.

Approximately 81 percent of the Company's 2008 revenues came from coal sales to electric utility companies and 19 percent came from coal sales to industrial and other companies or from synfuel handling fees. In 2008, James River Coal Co. produced 11.1 million tons of coal (including 0.2 million tons of coal produced in their mines operated by contract mine operators) and the company purchased another 0.2 million tons for resale.

Formed in 1988 through the purchase of McCoy Elkhorn and Bell County from Transco Coal Company, in 1992 the Company acquired the operations of Johns Creek Coal Company and the Bevins Branch Preparation Plant.  Both of these are now in operation under McCoy Elkhorn. In June of 1995, the acquisition of Leeco and Bledsoe operating companies took place through Transco Coal Company.

The Blue Diamond operating company became part of James River Coal Co. in 1998. In 1999, they acquired Shamrock Coal Company. This added mines, reserves, and a preparation plant and the Clover load out facility to the Bledsoe complex. In addition, the purchase of Triad took place in May of 2005. James River Coal Co. acquired Cheyenne Resources in 2008.

James River Coal Co. (JRCC) closed Friday's trading session at $18.41 up 1.04 percent. Volume was 1,017,799.

Turbine Truck Engines Inc. (TTEG)

Penny Stock Chaser, SmallCap Voice, Standout Stocks, The Street, Stock Marketing Inc., Topgun stockpicks, and Stock Stars reported earlier on Turbine Truck Engines Inc. (TTEG), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Turbine Truck Engines, Inc. is a technology company focused on the development, manufacture, and testing of their environmentally-friendly turbine-based truck engine. This engine is for mass market distribution in the United States and abroad. The primary business of the Company is the commercialization of Alpha Engines Corporation’s (Alpha) Detonation Cycle Gas Turbine (DCGT) engine for heavy-duty trucks with power ranges from 300 to 1,000 horsepower. Turbine Truck Engines Inc. trades on NASDAQ's OTC Bulletin Board and they have their corporate headquarters in DeLand, Florida.

The Detonation Cycle Gas Turbine (DCGT) engine has patented cyclical detonation technology. The new engine can utilize any known fuel source. This includes gasoline, diesel, propane, natural gas, hydrogen, methanol, ethanol or LPG. It can also use a fuel mixture. However, it needs no coolant, lube oil, filters, or pumps. Its unique, lightweight turbine design has few moving parts, which significantly reduces maintenance costs. The innovative cyclic detonation process produces a complete combustion of fuel-oxidizer mixtures, resulting in greater fuel economy and fewer harmful exhaust emissions.

The DCGT engine uses over 30 percent less fuel than current engine technologies. It significantly reduces nitrogen oxide (NO, NO2, N2O2) and carbon monoxide (CO) emissions, has a high power-to-weight ratio, and is air cooled. The engine also has cold start capability.

On December 9, 2009, Turbine Truck Engines, Inc. discussed how the need for electricity would continue to grow and companies that are successful in creating technologies that encompass innovative and economical methods to generate electricity while minimally affecting the environment will share in the windfall profits that follow technological successes. Turbine Truck Engines recently signed a Strategic Alliance Agreement with Genes Guohao Technology Co. Ltd. This is to explore the possibility of utilizing their turbine technology for electrical power generation.

Michael Rouse, President and CEO of Turbine Truck Engines, observed, "Our alliance with Guohao opens up a world of possibilities, and we are seeking additional alliances that would utilize our engine to generate electricity. Our technology is capable of using any fuel that can be gasified in an efficient and environmentally friendly manner and we are excited about the role our engine may play in the transformation of the energy landscape."

Today, Turbine Truck Engines Inc. (TTEG) closed trading at $0.38 up 8.57 percent. Volume was 44,870.

Sunesis Pharmaceuticals Inc. (SNSS)

OTC Picks, The Dean, Hit and Run Candle Sticks, Stock Fortune Teller, CRWE Finance, Stock Rich, Cool Penny Stocks, Penny Invest, Stockpalooza, Microcap Voice, Greenbackers, StockEgg.com, and HotOTC.com all reported this month on Sunesis Pharmaceuticals Inc. (SNSS), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company that trades on the NASDAQ Capital Market. The Company is focusing on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company is advancing their drug candidate Voreloxin in multiple indications to improve the lives of people with cancer. Founded in 1998, Sunesis Pharmaceuticals Inc. has their headquarters in South San Francisco, California.

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD. This is a class of compounds not used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest, and apoptosis. Voreloxin is currently undergoing evaluation in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients. It is also undergoing evaluation in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

Another product the Company has in development is SNS-314. This is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis. This leads to multiple rounds of endoreduplication and eventually cell death.

On December 7, 2009, Sunesis Pharmaceuticals, Inc. announced positive data from two Phase 2 clinical trials of the Company's lead drug candidate, Voreloxin. The results highlight Voreloxin's strong efficacy and safety profile when used as a single agent or in combination with chemotherapy. This is in patients with difficult to treat acute myeloid leukemia (AML). The presentation of the trial results was at the 51st American Society Hematology (ASH) Annual Meeting in New Orleans, Louisiana.

"These results provide us with the efficacy and safety data to move Voreloxin forward into pivotal testing," said Steven Ketchum, Ph.D., Senior Vice President of Research and Development at Sunesis.

Sunesis Pharmaceuticals Inc. (SNSS) closed today's trading session at $1.50 down 6.25 percent. Volume was 6,711,841.

Somaxon Pharmaceuticals, Inc. (SOMX)

Last week Greenbackers and Today's Financial News reported on Somaxon Pharmaceuticals, Inc. (SOMX), Cool Penny Stocks, Momentum Traders, Stock Market News Alert, SmallCapInvestor.com, HotOTC.com, Hit and Run Candle Sticks, Stock Rich did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2003, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development, and commercialization of proprietary branded pharmaceutical products and late-stage product candidates. These are for the treatment of diseases and disorders in the central nervous system therapeutic area. Trading on the NASDAQ Capital Market, the Company has their corporate headquarters in San Diego, California.

Somaxon Pharmaceuticals, Inc.'s lead product candidate is Silenor® (doxepin) for the treatment of insomnia. Silenor is a sleep-specific, low-dose (3mg and 6mg), oral tablet formulation of doxepin that is patent-protected for use in insomnia. Silenor is a potent antagonist that appears to block histamine selectively at the H1 receptor without a clinically relevant impact on other neurotransmitter systems. Doxepin at higher doses has been associated with a range of pharmacologic side effects. These include anticholenerigic effects (dry mouth, constipation, etc.) and weight gain.

The Company is committed to securing an established commercial partner for Silenor in the United States. They will consider co-promotion and licensing structures that provide upfront and milestone payments, royalties, and cost sharing as appropriate. Somaxon may also actively evaluate in-licensing of commercialized products and late-stage product candidates in the central nervous system therapeutic area.

Yesterday, Somaxon Pharmaceuticals, Inc. stated that they have a meeting scheduled with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia. On December 4, 2009, Somaxon received a Complete Response Letter from the FDA. The FDA stated that they could not approve the NDA in its present form. Somaxon previously received a Complete Response Letter for the NDA in February 2009, and they resubmitted the NDA in June 2009.
Somaxon is seeking a pathway for potential approval of the NDA, focusing on alternatives that utilize the clinical data submitted to the FDA to date. The Company reported that they would provide an update regarding their discussions with the FDA relating to the Silenor NDA promptly after the Company has analyzed the feedback they receive at the meeting.

Somaxon Pharmaceuticals, Inc. (SOMX) closed Friday's trading session at $1.10 up 11.09 percent. Volume was 2,156,275.

The QualityStocks Company Corner

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH) Today, Consorteum Holdings, Inc. closed trading at $0.0250, which was up 66.67 percent. Their volume today was 10,000 shares.

Consorteum Holdings, Inc. (CSRH) is focused on providing financial services, electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. The company's services provide customized, innovative technology solutions that create, augment and enhance their clients' existing financial, payment and transactional processing systems.

The company offers clients a long-term strategic plan utilizing the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create exceptionally customized programs. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new revenues.

Consorteum's strategy is to capitalize on the global opportunities within the growing financial services, payment and transaction processing marketplace. The utilized business model generates revenues on every transaction touched, thus providing long-term, sustainable income. The company has strategically designed its business initiatives to create significant repetitive transactions on an ongoing basis. Additional company revenues are generated from consulting services, project minimums and management fees.

The company is jointly led by CEO Craig Fielding and President & COO Quent Rickerby. Mr. Fielding brings a wealth of expertise in the payments industry, in both local and international payment processing, along with HR-specific business management expertise, leadership, customer development and acquisition skills. Mr. Rickerby brings over two decades of business management, international and domestic sales experience, new company start-up, payment processing, project management, business development, negotiations, relationship management and strategic company direction.Disclaimer

Consorteum Holdings, Inc. Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Inc. Provides Investor Update on Initial North American Contracted Projects

Consorteum Holdings Inc. Launches Alternative Mail-In Rebate Program for Manufacturers and Retailers

Consorteum Holdings Inc. Provides Manufacturer and Retailer Solutions in North America and Europe

Muscle Flex Inc. (MFLI)

The QualityStocks Daily Newsletter would like to spotlight Muscle Flex Inc. (MFLI). Today, Muscle Flex Inc. closed trading at $0.0150, which was up 15.38 percent. Their volume today was 1,712,889 shares.

Muscle Flex Inc. (MFLI) announced today that they have released parts one and two of the BUDDY Tablet Caddy viral online commercial. It is available for viewing at the following link: http://www.youtube.com/MuscleFlexTV

Muscle Flex Inc. (MFLI) is a leading edge fitness, health and lifestyle company focused on developing exciting brands and new products to market using direct response TV advertising and infomercials as well as cutting edge brand and image marketing. The company has designed all its products with the average person's lifestyle in mind.

Muscle Flex Inc. VATA Brasil sports and active wear collection is an ultra comfortable active wear line that utilizes superior moisture control fabric. The VATA Brasil OneFit fabric is an amazing innovation in sporting wear apparel, offering the advantages of being lightweight, highly elastic, and having four times the filaments than regular fabric.

The company’s newest product, The BUDDY Tablet Caddy™, is a personal, compact and portable tablet caddy with three individual compartments and a digital timer to remind users when it’s time to take vitamins or prescriptions. The pharmacist approved tablet caddy ensures the maximum effectiveness of all medications and supplements.

Founder and CEO Danny Alex leads the company with nearly three decades of experience in the health, fitness and athletic lifestyle. Since a young age, regular exercising and maintaining a healthy lifestyle has been a key part of Danny’s life. Today, it is his passion to help others get excited about themselves through fitness and healthy living. Disclaimer

Muscle Flex Inc. Blog

Muscle Flex Inc. News:

Muscle Flex Releases Parts One & Two of the BUDDY Tablet Caddy Viral Video Online Commercial on YouTube.com; Medical Marijuana and Zapping Grandpa

Muscle Flex to Release the Beagle StepFit, the BUDDY Tablet Caddy and Muscle Flex VATA Brasil in January 2010

Muscle Flex Inc. Calls the Initial Test of the Beagle StepFit "Successful"

Newport Digital Technologies, Inc. (NPDT)

The QualityStocks Daily Newsletter would like to spotlight Newport Digital Technologies, Inc. (NPDT). Today, Newport Digital Technologies, Inc. closed trading at $0.0270, which was up 2.66 percent. Their volume today was 704,237 shares.

Newport Digital Technologies, Inc. (NPDT) provided an update on the launch of their first RFID ready, handheld computing device. The Company announced that they anticipate that they will have their military rugged handheld N37B computing device complete the AT&T device certification on December 14th, 2009.

Newport Digital Technologies, Inc. (NPDT) offers a rich portfolio of competencies in RFID (Radio-Frequency Identification), WiMAX, eLearning, LED Signage, and Security & Surveillance. Utilizing its technological expertise and creativity, the company enables its customers to take full advantage of the nearly limitless possibilities offered by increasingly sophisticated applications.

Newport is committed to meeting specific customer requirements by delivering complete solutions for a broad spectrum of applications. The company is building a global distribution, licensing, and sales network of industry-leading partners as well as third-party Original Design Manufacturers (ODMs) and component suppliers to ensure its clients world-leading technology with strong local support capabilities.

The company has established a synergistic partnership with Taiwan’s premier technology incubators, the Institute for Information Industry (III) and the Industrial Technology Research Institute (ITRI), under which the company develops and customizes their advanced technologies to meet the needs of businesses across the globe. Having a pool of more than 7,900 engineers and scientists, these R&D powerhouses have developed cutting edge capabilities in fields such as Information Communications Technology (ICT), electronics, and nanotechnology.

Newport’s management team has accumulated a wealth of knowledge and experience within the technology industry as well as the corporate world. Maintaining a strong track record of delivering results to investors and customers, the team retains over two centuries of combined experience. Leveraging each team member’s area of expertise, Newport has established a solid foundation to penetrate emerging technology markets.Disclaimer

Newport Digital Technologies, Inc. Message Board

Newport Digital Technologies, Inc. Blog

Newport Digital Technologies, Inc. News:

Newport Digital Technologies Provides Update on Launch of N37B Rugged Handheld Computing Device; Nears Completion of AT&T Device Certification

SCIA "Saturday Winter Conference" Is a Success

Newport Digital Technologies, Inc. Announces Strategic Change in Senior Management Team as It Prepares for Launch of Its RFID and Wireless Digital Signage Products and Solutions

Royal Quantum Group, Inc. (RYQG)

The QualityStocks Daily Newsletter would like to spotlight Royal Quantum Group, Inc. (RYQG) Today, Royal Quantum Group, Inc. closed trading at $0.10, which was up 5.00 percent. Their volume today was 43,761 shares. 

Royal Quantum Group, Inc. (RYQG) is focused on acquiring, exploring and developing resource properties located within favorable geo-political climates. Led by a highly skilled, experienced board and management team, the company is strategically positioned to benefit from rising commodity prices.

The company currently has two oil and gas prospects located on the Nemaha Ridge in North Central Oklahoma. The Nemaha Ridge is characterized by a number of pay zones at relatively shallow depths. In the mapped area, eight different horizons have been found to be productive of oil and gas.

Royal Quantum Group, Inc. (RYQG) Bond Prospect is considered a low risk investment with at least ten different formations productive in the prospect area. The location has been interpreted to have the potential to hold more than 80,000 barrels of recoverable oil, plus gas valued at 20 to 30 percent of oil reserves.

The company is committed to creating value for its shareholders by building a portfolio of resource properties with the objective of advancing them to profitability. Royal Quantum Group’s management has a history of successfully managing early stage mineral exploration companies, and has great potential to lead the company to greater success. Disclaimer

Royal Quantum Group, Inc. Blog

Royal Quantum Group, Inc. News:

Royal Quantum Group, Inc. (RYQG) to be Featured in Small Cap Stock Newsletter QualityStocks Daily

(OTCBB: RYQG) Begins Oil Extraction on Oklahoma Well

/ CORRECTION - Royal Quantum Announces Successful Completion of Bond #1-18

Myriad Pharmaceuticals Inc. (MYRX) Announces Acquisition of Javelin Pharmaceuticals Inc.

Myriad Pharmaceuticals Inc. is a biotechnology company focused on the development of drugs for cancer, HIV and other medical conditions. The company today announced an acquisition agreement with Javelin Pharmaceuticals (AMEX: JAV), a company engaged in innovative technologies to develop new drugs for the pain management market.
Javelin has one marketed drug in the U.K., Dyloject, an injectable treatment for postoperative pain, as well as two drug candidates in U.S. advanced clinical development. On December 2, 2009, Javelin submitted a New Drug Application with the FDA for Dyloject.

Myriad’s acquisition of Javelin complements Myriad’s portfolio of product candidates, and is expected to benefit both companies.
“We believe that this transaction represents a highly effective vehicle to unlock the long-term potential of Myriad Pharmaceuticals and near-term value of Javelin Pharmaceuticals,” Adrian Hobden, Ph.D., president and CEO of Myriad stated in the press release. “Myriad is well positioned to successfully launch Dyloject upon FDA approval by leveraging our financial resources and the expertise of our core commercial team. In turn, we believe that potential Dyloject revenue will support the development of our existing clinical stage drug candidates MPC-4326, Azixa, and MPC-3100.”

Martin Driscoll, CEO of Javelin Pharmaceuticals, added, “This agreement creates a fully integrated biotechnology company with a submitted NDA for approval of a specialty care product, Dyloject, backed by significant financial resources, a broad pipeline for growth, and a seasoned management team for future commercialization efforts.”
Ed Swabb, chief medical officer of Myriad, said Dyloject has the potential to be an integral addition to the postoperative pain market.

“Dyloject has demonstrated a very exciting profile in controlled studies showing statistically significant results in two registration trials, which have been submitted to the FDA for approval consideration earlier this month,” Swabb stated. “If approved, Dyloject will be an important tool in the therapeutic armamentarium for multimodal management of postoperative pain.”

The acquisition is expected to close in the first quarter of 2010.

New Export Division to Launch at General Automotive Company (GNAU)

One company that has started to climb up the ladder is General Automotive Company. Based in Orlando, Florida, General Automotive is focused on expanding its operating growth platform through multiple and ongoing acquisitions of successful niche manufacturing companies within the automotive industry.

Today, General Automotive Company took a major step towards enhancing their future with the announcement that they have launched an export sales division for the purpose of expanding its distribution abroad.

From a historical standpoint, General Automotive Company has maintained its sales and distribution efforts within the borders of the United States but with this announcement, the young company has the potential to exploit the international distribution of its products and potentially grow into a global power.

Leading the way at General Automotive is Dan Valladao who serves as the company President and CEO. Valladao is a renowned name in the industry and has over 25 years of automotive experience, including in the retail, wholesale and OEM sales channels, and was instrumental in increasing the company’s sales from just over $3 million in 2004 to $15 million in 2007.

When asked what the new export division will mean to the future of General Automotive, Valladao was quoted as saying, “We have launched this initiative in response to demand that we see developing for our products internationally. With this new division, we will be able to leverage our existing relationships in Europe and Asia to expand our revenue and customer base.”

Another leader working at General Automotive is Scott Bruno. An industry veteran, Bruno has been appointed Director of Sales and has brought a full sales team with the agenda of building the export division. With the growth of the market, General Automotive is firmly positioned to take advantage of the wealth of opportunities presented.
Currently, General Automotive Company is trading in the $0.13 range. With strong leadership in place and the potential to evolve into a global presence, General Automotive may be an over-the-counter steal for the savvy investor.

ERF Wireless (ERFW) Receives $4.7+ Million Order for Mobile Broadband Trailers

ERF Wireless, a leading provider of enterprise-class wireless and broadband products and services, announced earlier today that the company entered into a $4.740,250.00 agreement with a major manufacturer to produce additional Mobile Broadband Trailers (MBTs) that will deploy the company’s high-speed wireless broadband digital-oilfield solutions into oil and gas drilling operations throughout North America.

According to Dr. H. Dean Cubley, CEO of ERF Wireless, “This agreement underscores the financial commitment ERF Wireless has made to expand the company’s capability to service the communications requirements of all its oil and gas drilling customers throughout North America, under existing as well as future contracts, with its full array of premier wireless broadband products and services.”
Dr. Cubley noted that the company has already amassed the largest terrestrial wireless broadband network covering the major oil and gas regions in North America through 15 network acquisitions and a continuing series of Master Service Agreements with other leading wireless providers. Earlier this year, ERF Wireless entered into an exclusive reseller contract with the world’s leading oil and gas service company to supply wireless broadband communications services to its customers throughout North America.

“By initiating the production of a large number of MBT units, which we will deploy along with our existing fleet, ERF Wireless has taken the next major step, in our continuing plan, to become the wireless broadband communications solution of choice for the oil and gas industry in North America,” said Dr. Cubley. “We fully expect in 2010 that the ERF Wireless Oil & Gas Services division will become the most profitable segment of our overall business strategy, which includes regional banking institutions, the healthcare industry and educational institutions as well as commercial and residential customers in rural communities throughout the country.”

“In addition, other areas these MBTs will be used for will include disaster recovery teams, first responders, pipeline and road construction, as well as special events. They can be utilized anywhere that a mobile communications capability is needed.” Cubley added, “After Hurricane Ike we utilized the MBTs to provide coverage to the Bolivar Peninsula just east of Galveston where the community was devastated and communications were non-existent for nearly 12 months following the storm.”

Arrayit Corp. (ARYC) Subsidiary Releases Timeline for OvaDx™ Product

Yesterday, Arrayit Diagnostics, a majority-owned subsidiary of Arrayit Corporation released its anticipated timeline for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian Cancer Blood Test. CEO John Howell formally commented on the time line and the blood test, which is currently in late-stage development. The rights to OvaDx™ have been assigned exclusively to the company by Arrayit Corporation.

Howell stated, “In response to numerous inquiries received from the medical, research and investor communities following last week’s exciting news announcements, we are pleased to confirm that Arrayit Diagnostics will file for Pre-Market Approval of our early stage ovarian cancer test as an ‘In Vitro Diagnostic Multivariate Index Assay’ shortly after the end of this year.”

He continued, “Notwithstanding any unexpected delays with the 510(k) review and approval process, we are optimistic that we will be in position to begin marketing the test for research purposes late in the first quarter of 2010, followed by official commercial launch to the medical diagnostics industry as early as the third quarter of 2010.”
According to the National Cancer Institute, ovarian cancer will affect over 21,000 women in the United States this year. During its initial stages of progression, ovarian cancer shows non-specific symptoms; however, no adequate screening or diagnostic test for early stage detection currently exists on the market. Consequently, most ovarian cancers are diagnosed only when later stage symptoms manifest, lowering the five-year survival rate for late stage diagnosis to less than 20%. Comparatively, early stage identification is approximately 90% survival rate if the disease is identified at the earliest stages. Arrayit Diagnostics hopes that its OvaDx™ product will answer the call for necessary early-stage testing.

Regarding the company’s marketing strategy, Howell added, “With plans to market the test at a cost of approximately $350 per test kit – and presuming we achieve our predetermined time-to-market objectives, we are confident that revenue of $4-$5 million is an attainable sales goal for 2010. Moreover, given that we estimate the total market for a viable early stage ovarian cancer screening test in the U.S., Japan and Europe could collectively represent use of up to 175 million kits per year; beyond 2010, annual revenues for Arrayit Diagnostics could ultimately reach into the hundreds of millions, and perhaps even billions, of dollars.”

 


Sponsors of the Day

 

The QualityStocks Public Company Sponsor News

QualityStocks


 

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336